Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 8/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11891102 | 0.90 | SMN1; SMN2 (0.42) | SMN1; SMN2KCNA5KCNH2 | |
| SCHEMBL1482980 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2KCNA5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11891091 | 0.76 | CYP11B1 (0.39) | SMN1; SMN2KCNA5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13089069 | 0.76 | CYP11B1 (0.39) | SMN1; SMN2KCNA5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16460462 | 0.75 | SMN1; SMN2 (0.59) | SMN1; SMN2GAAKCNA5CFTRSLC6A2 | |
| SCHEMBL3026300 | 0.75 | TSHR (0.34) | SMN1; SMN2GAATSHRLMNAL3MBTL1 | |
| SCHEMBL2204312 | 0.73 | ADRA2A (0.47) | GAATSHR | |
| SCHEMBL477633 | 0.73 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAKCNA5CFTRSLC6A2 | |
| SCHEMBL30476558 | 0.73 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAKCNA5CFTRSLC6A2 | |
| SCHEMBL477393 | 0.73 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAKCNA5CFTRSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155715-B1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | ALLERGAN INC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20100273814-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | SINHA SANTOSH C | 2010-10-28 | — | — | US | disclosed |
| US-20100273814-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | SINHA SANTOSH C | 2010-10-28 | — | — | US | disclosed |
| US-20100273814-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | SINHA SANTOSH C | 2010-10-28 | — | — | US | disclosed |
| EP-2155715-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | ALLERGAN, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008141312-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | ALLERGAN, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273814-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | CYP11B2, TPMT, COXFA4L2 | SMN1; SMN2 2674/4885GAA 362/4885KCNA5 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.